Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — H.C. Wainwright 23rd Annual Global Investment Conference 2021
32 slides from Nemaura Medical's conference presentation, Sep 10, 2021
Slide 1: H.C. Wainwright 23rd Annual Global Investment Conference
H.C. Wainwright 23 rd Annual Global Investment Conference 13 - 15 September 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms such
Slide 3: Background: About the CEO
Background About the CEO… Trained as a Drug Formulation Scientist Masters in Microsystems and Nanotechnology, Cranfield University UK Doctorate in Nanomedicine and Drug Delivery, University of Oxford First patent: Super - absorbent tablets during undergraduate internship at 3M Healthcare Currently >
Slide 4: Introduction
Introduction We developed the world’s first Daily - Wear non - invasive Continuous Glucose Monitor (CGM) – Class 2b CE approved Medical Device. Launched: sugarBEAT ® and BEAT ® diabetes , supporting Diabetes prevention, management and reversal. Planned Launch in 2021: Mass Market consumer metabolic
Slide 5: The Problem
The Problem… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the US alone in 2019 for diabetes related healthcare expenditure 1 . The total addressable market exceeds $ 150 Billion 2 , 3 , 4 . Obesity and Diabetes are two of the major drivers of
Slide 6: Our Objective: Prevent, Manage, or Reverse Type 2 Diabetes
Our Objective: Prevent, Manage, or Reverse Type 2 Diabetes
Slide 7: Our Unique Solution
UNIQUE The world’s first daily wear CGM: no other sensor technology is currently available allowing non - invasive daily use. LIFESTYLE Other competing sensors are worn for 10 - 14 days consecutively. Nemaura’s BEAT® sensors are designed for daily use – any day you choose. Our Unique Solution KNOWLE
Slide 8: Our Approach
Our Approach 1. sugarBEAT ® CGM – real time glucose monitoring. 1. BEAT ® diabetes – Digital program for diabetes management and reversal, with intermittent glucose profiling. 1. Mass market consumer metabolic health program, targeting obesity, pre - diabetes and Type 2 diabetes.
Slide 9: Total Addressable Market
Total Addressable Market UK 4.8 million people with diabetes 8 One person diagnosed every 2 minutes Germany 9.5 million have diabetes 9 . 4.5 million of these 9.5 million are undiagnosed and, as a result, may be particularly at risk. U.S. 34.2 million have diabetes 6 88 million people have pre - dia
Slide 10: Impact on Healthcare Cost
Impact on Healthcare Cost □ Healthcare costs for persons with Type 2 diabetes cost approximately 2.5x as much as a person without diabetes. If they experience complications, that number soars even higher 10 □ Employers and healthcare insurers are therefore resorting to programs that will provide lon
Slide 11: Product Portfolio
Product Portfolio sugarBEAT® CGM BEAT ® diabetes Program Consumer Metabolic Health Program
Slide 12: CE Approved Class IIB Medical Device
CE approved Class IIB Medical Device US FDA PMA approval and launch in the US anticipated by end of 2021 The world’s first daily wearable Continuous Glucose Monitor that doesn’t use needles. CE Approved Class IIb Medical Device
Slide 13: How it works
How it works Apply the sensor Position the daily disposable Sensor and Transmitter on your arm.
Slide 14: How it works
How it works @ See changes as they happen Helps you understand ee your unique glucose 2 foe (94) Gs trend line and lifestyle SS choices taken.
Slide 15: How it works
How it works YesYouCan BEAT™diabetes B contr manage, take d even prevent the onset of Type 2 Diabetes.
Slide 16: sugarBEAT and Time in Range
sugarBEAT ® and Time in Range A critical advantage of CGM - based systems is the ability to measure the time that glucose levels are in normal range – i . e . , time in range (TIR) . Control over TIR leads to a significant reduction in the onset of complications of diabetes . The same HbA 1 C values
Slide 17: sugarBEAT vs. HbA1C
sugarBEAT ® vs. HbA1C 40% high range 40% in range 20% low range 70% high range 25% in range 5% low range 100% in range The same HbA1C value, yet 3 completely different TIR profiles, demonstrating the power of TIR over HbA1C as the new gold standard 11
Slide 18: sugarBEAT Testimonials
sugarBEAT ® Testimonials My Sugar Watch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, and
Slide 19: sugarBEAT Sales Status UK
sugarBEAT ® Sales status UK UK: 200,000 Sensors ordered by licensee following soft launch success Purchase order forecast for (approximately) a further 100,000 per month for the next 2 years, totaling over 2 million sensors. Licensee selling these based on a diabetes management subscription service.
Slide 20: sugarBEAT Outside UK
sugarBEAT ® Outside - UK Expecting to reveal launch plans for direct to consumer launch of sugarBEAT outside of UK, next Q. Update on reimbursement strategy in key territories.
Slide 21: Type 2 Diabetes prevention and management program launched in the U.S.
Type 2 Diabetes prevention and management program launched in the U.S.
Slide 22: BEAT diabetes – Components
BEAT ® diabetes – 3 Components 1. Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence (based on an in - clinic program, subsequently replicated using a virtual program). Sustained long term weight loss achieved without loss of muscle mass 1. pr
Slide 23: BEAT diabetes – Glucose Profiling
BEAT ® diabetes – Glucose Profiling Intermittent Glucose Profiling: Benefits 7 - point glucose profiles every 4 weeks. Patients received guidance for diet and exercise adjustments based on Self - monitoring of blood glucose (SMBG). Outcome: Significant reductions in HbA1c, weight, BMI, systolic BP,
Slide 24: BEAT diabetes Potential Outcome for Payers
BEAT ® diabetes Potential Outcome for Payers Healthier Employees = Healthier Business $1,600 $4,700 $6,600 $9,100 Healthy (No conditions) Prediabetes only Hypertension Only Diabetes Only Annual Cost per Employee On average, diabetes costs both employers and insurers over $9,000 per year. Potential s
Slide 25: BEAT diabetes Current Status
BEAT ® diabetes Current Status Pilot study in the US in progress, using proBEAT and digital health app. Expecting to report plans for large scale adoption thereafter
Slide 26: BEAT Metabolic Health
BEAT Metabolic Health Metabolism is life. Can we help 87 MILLION people in the USA from becoming Diabetic using our low cost wearable glucose sensor and digital ecosystem?
Slide 27: Metabolic Health: A mass-market consumer product
Metabolic Health A mass - market consumer product A new program leveraging off the BEAT® wearable sensor platform to address improvements in metabolic health and well - being . Launching in 2021. Applicable to over 80 million people in the US with pre - diabetes as well as general health - conscious
Slide 28: Future Product Opportunities Leveraging the BEAT Technology
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 29: Future Product Opportunities Leveraging the BEAT Technology
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits . Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Globa
Slide 30: The Team
The Team We are building a world class team So far includes senior level appointments, with experience from companies including: Dexcom, Lifescan , Roche, Abbvie , & Eli Lilly
Slide 31: Summary
Summary 1. UK Order fulfillment and sales progress to be provided 1. Launch in Outside - UK territories (with CE mark) in progress 1. Next steps for BEAT ® diabetes program and adoption/marketing plans for insurers and Employers in the USA to be issued next quarter 2. FDA PMA status update to be pro
Slide 32: References
References 1. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures. htm! 3. https://www.prnewswire.com/news-releases/global-digital-diabetes-market- outlook-to-2026-a-16-billion-industry-opportunity-300980794.htm! 4, https://www.absolutemarketsinsights.com/reports/Global-Noninsulin- ‘The
Nemaura Medical — H.C. Wainwright 23rd Annual Global Investment Conference 2021 on 6ix